Indications

The vaccine is indicated for active immunization against infection caused by HAV in persons over age of 18 months.

Highlights

•  H2 strain is recognized by WHO

•  Only one dose is needed to provide sufficient immune protection against hepatitis A

•  Safety and efficacy had been proven in a 15- year clinical observation in China

•  70% market share in China

•  Marketed in India, Uzbekistan, Pakistan, Philippines, Guatemala and etc;

•  Being registered in Thailand, Vietnam, Salvador, Honduras, Nicaragua, Dominican Republic

•  Recommended by Indian Academy of Pediatrics (IAP)

•  Complete phase I, II, III, IV Clinical Trial conducted in China

Specification

After reconstitution in vial form, each 0.5 ml/dose contains hepatitis A live attenuated vaccine ≥ 6.5 LgCCID50.

Dosage Form

Freeze-dried powder for Injection.

Route of Administration

Intramuscular injection.

Shelf life

24 months.